Decisions made at the extraordinary meeting of the shareholders

DECISIONS MADE AT THE EXTRAORDINARY MEETING OF THE SHAREHOLDERS * Issue of 150,000 subscription options for senior management. * Issue of 120,000 personnel options for employees and advisors in USA. * Authorization for the Board to make a new issue of a maximum of 1,280,000 shares in order to enable a company acquisition. At today's extraordinary meeting of the shareholders of Q-Med AB (publ) the meeting decided in accordance with the Board's proposal to issue two options programs, one consisting of subscription options and one consisting of personnel options. Furthermore, the meeting authorized the Board to decide to make a new share issue, up until the time of the next Annual General Meeting. OPTIONS PROGRAM Subscription options It was decided to issue a maximum of 150,000 options, where each option gives the right to subscribe for one share in Q-Med. Subscription for the shares can take place from May 15 until September 30, 2004. The redemption price amounts to SEK 366.80. An offer will be made to senior management to acquire options, with the number to be decided on an individual basis, but a maximum of 30,000 options each. Personnel options It was decided to issue a maximum of 120,000 personnel options to employees in senior management positions in and advisors linked to the business activities of the Q-Med Group in USA. Each personnel option gives the right to acquire one share in Q-Med AB. The issue will take place up until December 15, 2000. The options can be utilized during a period of seven years from the date of issue, where each owner has the right to utilize 25% of his holding as from a date one year after the date of issue and a further 25% as from that date each of the following three years. Non-utilized personnel options are forfeited in the event that the owner ceases to be an employee in a senior management position in or an advisor to the Q-Med Group. Employees in senior management positions in and advisors linked to the business activities of the Q-Med Group in USA will each be allocated a maximum of 50,000 personnel options. The options will be allocated on an individual assessment basis. In order to cover the financial risk for Q-Med, the company will issue a debenture together with in total a maximum of 150,000 separable options for subscription for new shares, where each option gives the right to subscribe for one new share in the company. Shares can be subscribed for as from the date of registration with the Swedish Patent and Registration Office until December 31, 2007. The redemption price amounts to SEK 183.40. If shares are subscribed for in exchange for all options, the company's share capital can be increased by SEK 300,000, corresponding to approximately 1.2% of the total share capital and the number of votes after full dilution. In the event of full subscription the total number of outstanding options corresponds to approximately 3.7% of the total share capital and number of votes after full dilution. The reasons for the deviation from the shareholders' pre-emptive rights are that the Board considers that Q-Med should promote its long-term interests by stimulating senior management in the Group and employees and advisors linked to the business activities of the Q-Med Group in USA to hold a stake in the company. AUTHORIZATION OF THE BOARD TO ISSUE SHARES IN CONNECTION WITH THE POSSIBLE ACQUISITION OF A COMPANY The meeting authorized the Board to decide to make a new share issue, on one or more occasions up until the time of the next Annual General Meeting, of in total a maximum of 1,280,000 shares, corresponding to approximately 5% of the company's share capital. The new issue may deviate from the shareholders' pre-emptive rights and may be paid for both in cash or in kind. The reason for the possible deviation from the shareholders' pre-emptive rights is to enable a company acquisition paid for in Q-Med's own shares and to secure the company's capital requirements. November 6, 2000 Uppsala, Sweden Q-Med AB (publ) Per Olof Wallström President and CEO Queries should be addressed to Per Olof Wallström, President and CEO, on +46(0)18-474 90 00 or +46(0)70-974 90 70. Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. All products are based on the company's patented technology for the production of NASHA - Non-Animal Stabilized Hyaluronic Acid. Q-Med's operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation. The products RESTYLANE, RESTYLANE Fine Lines and PERLANE are used for the filling out of lips and facial wrinkles and today account for the majority of sales. The development of MACROLANE for breast augmentation is ongoing. DUROLANE, Q-Med's product for the treatment of osteoarthritis in the knee-joint, is in the clinical documentation phase. DEFLUX is a product which has been approved in Europe for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children and stress urinary incontinence in women. Since July 2000 Q-Med has held a majority interest in the American biotechnology company Ixion Biotechnology, Inc., which carries out research within cell therapy for diabetes. Q-Med today has 175 employees, with 125 at the company's production facility and head office in Uppsala, 10 at Ixion and the remainder in wholly owned foreign subsidiaries. The Q-Med share has been listed on the O-list of the OM Stockholm Stock Exchange since December 1999. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Home page: www.q-med.com ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/11/06/20001106BIT00370/bit0001.doc http://www.bit.se/bitonline/2000/11/06/20001106BIT00370/bit0002.pdf

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.